Dutch Bio-Electronic Neurodegenerative Filter (DBNF – Patented Technology)
The Dutch Bio-Electronic Neurodegenerative Filter (DBNF) is in the research and development phase as a technological concept designed to study and interpret neural and neuromuscular signal patterns associated with movement-related neurological mechanisms. The platform is being developed to explore how voluntary and involuntary neural activity can be registered, analysed and differentiated within a controlled research environment, supported by AI-based data processing.
The DBNF concept includes specially engineered components such as Dual Nerve Cuffs and electrode structures that are designed to enable continuous signal registration. Within this research framework, the system investigates how multi-modal signal inputs—such as neural activity, muscle responses and movement patterns—can be processed using algorithmic and data-driven models. These explorations focus on technical feasibility and on identifying potential patterns relevant for future neuroscientific studies.
As part of this R&D platform, several modules are being examined, including systems for:
– registering different types of neural and muscular signals
– exploring methods for distinguishing specific signal characteristics
– investigating algorithmic filtering approaches exclusively for research purposes
– adjustable signal-processing parameters controlled by authorised researchers
– secure wireless data readout within a research setting
– studying electromagnetic-field considerations for technical safety
– integrating AI-supported analytical tools for classification and pattern recognition
The DBNF technology is not intended for diagnosis, therapy, symptom management or clinical use. Its current development is fully dedicated to technical validation, signal-analysis research and the investigation of potential future applications in neurotechnology.
For research collaborations or additional information about the DBNF platform, please contact us.
This website is intended exclusively for business-to-business (B2B) communication.
The information provided is aimed at professional partners, research institutions, healthcare organizations and companies involved in innovation, valorisation and technology development. It is not intended for patients or general consumer use.
Confidentiality Notice
Due to the confidential nature of our patents, inventions, and R&D activities, not all projects and development phases are publicly disclosed.
EU-office:
Coolsingel 104
3011 AG Rotterdam

